Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp ADR (NQ: AMRN )

0.5486 +0.0237 (+4.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amarin Corp ADR

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday. 
Via Benzinga
Amarin Corp: Q2 Earnings Insights
  Amarin Corp (NASDAQ:AMRN) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Amarin Outlines $100M Cost Saving Plan
Via Benzinga
Recap: Amarin Corp Q1 Earnings
Amarin Corp (NASDAQ:AMRN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday. 
Via Benzinga
Sarissa Capital Intends to Vote “Abstain” at the Amarin Annual Meeting
From Sarissa Capital Management LP
Via Business Wire
Looking Into Amarin Corp's Return On Capital Employed
Amarin Corp (NASDAQ:AMRN) brought in sales totaling $94.63 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 314.74%, resulting in a loss of $31.56 million. 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022
Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Down; Jobs Report In Focus
Pre-open movers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Upgrades 
Via Benzinga
10 Biggest Price Target Changes For Thursday
Needham cut Cirrus Logic, Inc. (NASDAQ: CRUS) price target from $110 to $100. Cirrus Logic shares rose 4.5% to close at $82.81 on Wednesday. 
Via Benzinga
81 Biggest Movers From Yesterday
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday. 
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Jumps 5%; Fed Boosts Interest Rates By 0.5%
U.S. stocks traded mixed toward the end of trading, after the Federal Reserve announced its policy decision. 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday. Sharps Technology, Inc. (NASDAQ: STSS) rose 31.4% to $1.6815 after... 
Via Benzinga
Mid-Day Market Update: Dow Rises 100 Points; Lyft Shares Plummet
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Wednesday. 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points
U.S. stocks traded mixed this morning, with the Nasdaq dropping more than 100 points on Wednesday. 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Amarin Corp's Earnings: A Preview
Amarin Corp (NASDAQ:AMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Amarin Corp... 
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
NASDAQ:AMRN Long Term Investor Notice: Investigation of Potential Wrongdoing at Amarin Corporation Plc
San Diego, CA -- (SBWIRE) -- 03/09/2022 -- An investigation was announced for investors in shares of Amarin Corporation plc (NASDAQ:AMRN) concerning potential breaches of fiduciary duties by certain... 
Via SBWire
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
Lower Vascepa Volume Hits Amarin's Q4 Topline Growth
Amarin Corp plc's (NASDAQ: AMRN) Q4 FY21 sales decreased 13.6% Y/Y to $144.49 million, beating the consensus of $141.75 million. The decline was driven primarily by... 
Via Benzinga
Amarin: Q4 Earnings Insights
Amarin Corp (NASDAQ:AMRN) reported its Q4 earnings results on Tuesday, March 1, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
28 Stocks Moving In Tuesday's Mid-Day Session
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares jumped 47.8% to $22.93 after the company unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic,... 
Via Benzinga
51 Biggest Movers From Yesterday
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.